Observational studyJournal of diabetes investigation2026
Efficacy of MiniMed™ 780G® on glucose management, sleep quality, and psychological aspects in persons with type 1 diabetes treated with MiniMed™ 770G®: A 3-month prospective single-center observational study.
Observational study in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DAGs and GRaSP Causal Inference Algorithms Combined and Applied to the Calculation of Insulin Bolus in Patients with Type 1 Diabetes.Entropy (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionThe MiniMed™ 780G® is effective for improving glycemic control; however, few studies have specifically examined the impact of upgrading from MiniMed™ 770G® to MiniMed™ 780G® in adults. We determined the effects of upgrading from MiniMed™ 770G® to MiniMed™ 780G® (780G) on glucose management, psychological distress, daily life quality, and sleep in type 1 diabetes mellitus (T1DM). MATERIALS AND
methodsIn this single-center prospective study, we observed 21 adults who transitioned from the MiniMed™ 770G® to the 780G for 3 months. Glycemic outcomes, insulin delivery parameters, frequency of alarms, and sensor calibrations were assessed. Patient-reported outcomes were evaluated using the Problem Areas in Diabetes (PAID), the Diabetes Treatment Satisfaction Questionnaire status version, the Diabetes Therapy-Related Quality of Life, and the Pittsburgh Sleep Quality Index.
resultsGlycated hemoglobin (HbA1c) decreased (7.5 ± 1.3%-7.0 ± 0.8%, mean difference: -0.5%, 95% Confidence Interval (CI): -0.9 to -0.1; P = 0.018). Time in tight range (TITR) showed trends toward improvement (44.9 ± 15.5%-48.9 ± 15.5%, mean difference: 4.0%, 95% CI: -0.7 to 8.6; P = 0.090). Alarm frequency declined (11.9 ± 8.7-7.1 ± 5.5 times/day, mean difference: -4.8, 95% CI: -7.0 to -2.6; P = 0.0002), and calibration frequency decreased (3.6 ± 2.2-0.8 ± 0.6 times/day, mean difference: -2.8, 95% CI: -3.7 to -1.9; P < 0.0001). The PAID score improved, decreasing from 38.7 ± 19.9 to 31.7 ± 19.3 (mean difference: -7.0, 95% CI: -14.7 to 0.7; P = 0.074).
conclusionsFavorable changes in HbA1c, TITR, and PAID scores suggest potential glycemic and psychological benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.